As of Feb 17
| +0.05 / +0.40%|
The 8 analysts offering 12-month price forecasts for Halozyme Therapeutics Inc have a median target of 14.50, with a high estimate of 20.00 and a low estimate of 6.75. The median estimate represents a +14.99% increase from the last price of 12.61.
The current consensus among 9 polled investment analysts is to Buy stock in Halozyme Therapeutics Inc. This rating has held steady since February, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.